272 related articles for article (PubMed ID: 24462217)
21. Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins.
Zeballos C MA; Moore HJ; Smith TJ; Powell JE; Ahsan NS; Zhang S; Gaj T
Nat Commun; 2023 Oct; 14(1):6492. PubMed ID: 37838698
[TBL] [Abstract][Full Text] [Related]
22. TDP43 proteinopathy is associated with aberrant DNA methylation in human amyotrophic lateral sclerosis.
Appleby-Mallinder C; Schaber E; Kirby J; Shaw PJ; Cooper-Knock J; Heath PR; Highley JR
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):61-72. PubMed ID: 32365404
[TBL] [Abstract][Full Text] [Related]
23. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis.
Güttsches AK; Brady S; Krause K; Maerkens A; Uszkoreit J; Eisenacher M; Schreiner A; Galozzi S; Mertens-Rill J; Tegenthoff M; Holton JL; Harms MB; Lloyd TE; Vorgerd M; Weihl CC; Marcus K; Kley RA
Ann Neurol; 2017 Feb; 81(2):227-239. PubMed ID: 28009083
[TBL] [Abstract][Full Text] [Related]
24. TDP-43 Proteinopathy Specific Biomarker Development.
Cordts I; Wachinger A; Scialo C; Lingor P; Polymenidou M; Buratti E; Feneberg E
Cells; 2023 Feb; 12(4):. PubMed ID: 36831264
[TBL] [Abstract][Full Text] [Related]
25. TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis.
Deshaies JE; Shkreta L; Moszczynski AJ; Sidibé H; Semmler S; Fouillen A; Bennett ER; Bekenstein U; Destroismaisons L; Toutant J; Delmotte Q; Volkening K; Stabile S; Aulas A; Khalfallah Y; Soreq H; Nanci A; Strong MJ; Chabot B; Vande Velde C
Brain; 2018 May; 141(5):1320-1333. PubMed ID: 29562314
[TBL] [Abstract][Full Text] [Related]
26. Interaction of RNA with a C-terminal fragment of the amyotrophic lateral sclerosis-associated TDP43 reduces cytotoxicity.
Kitamura A; Nakayama Y; Shibasaki A; Taki A; Yuno S; Takeda K; Yahara M; Tanabe N; Kinjo M
Sci Rep; 2016 Jan; 6():19230. PubMed ID: 26757674
[TBL] [Abstract][Full Text] [Related]
27. Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype.
Mann DMA; Snowden JS
Brain Pathol; 2017 Nov; 27(6):723-736. PubMed ID: 28100023
[TBL] [Abstract][Full Text] [Related]
28. TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes.
Tan RH; Kril JJ; Fatima M; McGeachie A; McCann H; Shepherd C; Forrest SL; Affleck A; Kwok JB; Hodges JR; Kiernan MC; Halliday GM
Brain; 2015 Oct; 138(Pt 10):3110-22. PubMed ID: 26231953
[TBL] [Abstract][Full Text] [Related]
29. Metabolome and transcriptome analysis on muscle of sporadic inclusion body myositis.
Murakami A; Noda S; Kazuta T; Hirano S; Kimura S; Nakanishi H; Matsuo K; Tsujikawa K; Iida M; Koike H; Sakamoto K; Hara Y; Kuru S; Kadomatsu K; Shimamura T; Ogi T; Katsuno M
Ann Clin Transl Neurol; 2022 Oct; 9(10):1602-1615. PubMed ID: 36107781
[TBL] [Abstract][Full Text] [Related]
30. Different Chronic Stress Paradigms Converge on Endogenous TDP43 Cleavage and Aggregation.
Candelise N; Caissutti D; Zenuni H; Nesci V; Scaricamazza S; Salvatori I; Spinello Z; Mattei V; Garofalo T; Ferri A; Valle C; Misasi R
Mol Neurobiol; 2023 Nov; 60(11):6346-6361. PubMed ID: 37450246
[TBL] [Abstract][Full Text] [Related]
31. RNA-binding proteins with prion-like domains in health and disease.
Harrison AF; Shorter J
Biochem J; 2017 Apr; 474(8):1417-1438. PubMed ID: 28389532
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional targets of amyotrophic lateral sclerosis/frontotemporal dementia protein TDP-43 - meta-analysis and interactive graphical database.
Cao MC; Scotter EL
Dis Model Mech; 2022 Sep; 15(9):. PubMed ID: 35946434
[TBL] [Abstract][Full Text] [Related]
33. TDP43 interacts with MLH1 and MSH6 proteins in a DNA damage-inducible manner.
Provasek VE; Kodavati M; Kim B; Mitra J; Hegde ML
Mol Brain; 2024 Jun; 17(1):32. PubMed ID: 38840222
[TBL] [Abstract][Full Text] [Related]
34. RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration.
Hofmann JW; Seeley WW; Huang EJ
Annu Rev Pathol; 2019 Jan; 14():469-495. PubMed ID: 30355151
[TBL] [Abstract][Full Text] [Related]
35. Mitochondrial DNA depletion in sporadic inclusion body myositis.
Bhatt PS; Tzoulis C; Balafkan N; Miletic H; Tran GTT; Sanaker PS; Bindoff LA
Neuromuscul Disord; 2019 Mar; 29(3):242-246. PubMed ID: 30850168
[TBL] [Abstract][Full Text] [Related]
36. Sporadic inclusion body myositis: clinical, pathological, and genetic analysis of eight Polish patients.
Kierdaszuk B; Berdynski M; Palczewski P; Golebiowski M; Zekanowski C; Kaminska AM
Folia Neuropathol; 2015; 53(4):355-66. PubMed ID: 26785370
[TBL] [Abstract][Full Text] [Related]
37. Motor neuron involvement in multisystem proteinopathy: implications for ALS.
Benatar M; Wuu J; Fernandez C; Weihl CC; Katzen H; Steele J; Oskarsson B; Taylor JP
Neurology; 2013 May; 80(20):1874-80. PubMed ID: 23635965
[TBL] [Abstract][Full Text] [Related]
38. TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration.
Gao J; Wang L; Yan T; Perry G; Wang X
Mol Cell Neurosci; 2019 Oct; 100():103396. PubMed ID: 31445085
[TBL] [Abstract][Full Text] [Related]
39. TDP-43: a DNA and RNA binding protein with roles in neurodegenerative diseases.
Warraich ST; Yang S; Nicholson GA; Blair IP
Int J Biochem Cell Biol; 2010 Oct; 42(10):1606-9. PubMed ID: 20601083
[TBL] [Abstract][Full Text] [Related]
40. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia.
Mackenzie IR; Rademakers R
Curr Opin Neurol; 2008 Dec; 21(6):693-700. PubMed ID: 18989115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
